linjc16/ctgov huggingface dataset:
Recovery of Biographical Memories Associated With a Melody: a Functional Magnetic Resonance Imaging Study

Study Overview
=================
Brief Summary
-----------------
This study aims to validate a functional MRI paradigm to determine the regions involved in the retrieve of music-linked memories

Official Title
-----------------
Recovery of Biographical Memories Associated With a Melody: a Functional Magnetic Resonance Imaging Study

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: Functional Magnetic Resonance Imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult men or women (aged 20 - 50) Signature of the study's informed consent form, accepting to not receive information with regards to any research results that are not clinically relevant. Persons that accept the study's procedure: magnetic resonance imaging. Exclusion Criteria: Contraindication to MRI scanning or conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.). Persons with severe or profound hearing loss or deafness

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cognitively unimpaired<br> | Other: Functional Magnetic Resonance Imaging<br>* Functional Magnetic Resonance Imaging<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fMRI paradigm |  | at inclusion |
Frequency of Diagnostic Symptomatic Pulmonary Embolism's in Patients Hospitalized for Clinical Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Study Overview
=================
Brief Summary
-----------------
A standardized diagnostic strategy of pulmonary embolism will be applied to eligible patients, incorporating a clinical probability score (revised Geneva score), plasma D-dimer assay and if necessary, a multidetector-row CT angiography thoracic and venous ultrasound of the lower limbs. All the patient with a pulmonary embolism diagnosed or not, will be followed for 3 months.

Official Title
-----------------
Frequency of Diagnostic Symptomatic Pulmonary Embolism's in Patients Hospitalized for Clinical Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Conditions
-----------------
Chronic Obstructive Pulmonary Disease, Patients Hospitalized for a COPD Exacerbation

Intervention / Treatment
-----------------
* Other: PEP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients hospitalized for a COPD exacerbation COPD previously diagnosed Exclusion Criteria: Allergy to iodinated contrast Creatinine clearance < 30 mL / min Patient hospitalized for exacerbation of COPD for more than 48 hours Pneumothorax Exams impossible to be performed Pregnancy Life expectancy < 3 months Patients already receiving anticoagulant therapy for another reason (mechanical valve, cardiac arrhythmia).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: PEP<br>No drug and no placebo were used in this study. For all the patients who participated at the study PEP, only following exams must be performed: a clinical probability score (revised Geneva score), plasma D-dimer assay and if necessary, a chest multidetector-row CT angiography and venous ultrasound of the lower limbs | Other: PEP<br> <br> * Other names: No drug and no placebo were used in this study. For all the patients who participated at the study PEP, only exams must be performed;;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of pulmonary embolism in patients hospitalized for a clinical exacerbation of COPD. |  | 27 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The rate of pulmonary embolism diagnosed during the 3 month follow-up in patients whom pulmonary embolism was initially excluded when they've been included in the study |  | 27 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD Exacerbation, Pulmonary embolism, Standardized and consensus diagnostic strategy
Comparison of Skinlink With Suture for ED Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether suture using the Device of Leukosan Skinlink is more faster and safer than that of nylon in the treatment of simple wound for ED patients.

Official Title
-----------------
Comparison of Skinlink With Suture for ED Patients: a Randomized Controlled Trial

Conditions
-----------------
Wounds and Injuries, Lacerations

Intervention / Treatment
-----------------
* Other: Skinlink
* Other: Nylon


Participation Criteria
=================
Eligibility Criteria
-----------------
The inclusion criteria were age 18-75 years,presence of a partial thickness laceration, generally good health without systemic abnormalities,agreement to return for a 14-day follow-up, and written informed consent. The exclusion criteria were previous diagnosis of diabetes mellitus, peripheral vascular disease, or bleeding disorders; history of keloid formation or scar hypertrophy; and allergy to cyanoacrylate compounds or formaldehyde

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Skinlink<br>applying Skinlink on simple laceration (length < 5cm) | Other: Skinlink<br>* suture using Skinlink<br>|
| Other: Nylon<br>applying conventional suture using nylon on simple laceration (length < 5cm) | Other: Nylon<br>* conventional suture using nylon<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time required to complete suture |  | 1year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dehiscence |  | 1year | 
| Infection rate |  | 1year |
IV and Intrathecal Ketamine in Cesarean Section

Study Overview
=================
Brief Summary
-----------------
In the current study, the investigators will compare the effects of low-dose intravenous (i.v.) ketamine versus intrathecal Ketamine added to spinal anesthesia on the time to first request for analgesia and maternal pain scores and overall satisfaction in patients undergoing cesarean section.

Official Title
-----------------
Comparison Between the Analgesic Effects of Intrathecal Versus Intravenous Ketamine After Spinal Anaesthesia for Elective Caesarean Delivery :a Randomised Trial

Conditions
-----------------
Cesarean Section, Analgesia

Intervention / Treatment
-----------------
* Drug: Intrathecal ketamine
* Drug: Intravenous ketamine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: • Pregnant undergoing elective cesarean section Exclusion Criteria Significant coexisting diseases (pregnancy-induced hypertension or diabetes) body mass index ≥40kg/m2, height <150cm Current use of pain medication including opioids history of substance abuse or hallucinations, cardiovascular disease, diabetes, multiple gestations chronic pain was excluded. contraindications to spinal anaesthesia, severely compromised fetus requiring general anesthesia and those patients who received labor analgesia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Intrathecal Ketamine<br>Patients will receive intrathecal Ketamine 0.1mg/kg added to bupivacaine and morphine. | Drug: Intrathecal ketamine<br>* Patients will receive intrathecal Ketamine 0.1mg/kg added to bupivacaine and morphine<br>|
| Active Comparator: Intravenous ketamine<br>Patients will receive IV Ketamine 0.25mg/kg after spinal anesthesia with bupivacaine and morphine. | Drug: Intravenous ketamine<br>* Patients will receive IV Ketamine 0.25mg/kg after spinal<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to the first analgesic request |  | First Postoperative day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative pain scores NRS at rest and on movement; (2, 4, 6, 12, and 24 hours) postoperative |  | first postoperative day |
Aesculus Hippocastanum L. on Fontan Circulation

Study Overview
=================
Brief Summary
-----------------
Patients after the Fontan operation at a single institution will be randomized to receive a standardized extract of Aesculus hippocastanum L. (horse chestnut) or placebo for 4 months in a crossover clinical trial. The primary outcome will be the mesenteric artery resistance measured by Dopple sonography.

Official Title
-----------------
Effect of Aesculus Hippocastanum L. (Sapindaceae, Horse Chestnut) on Fontan Circulation - a Randomized Clinical Trial

Conditions
-----------------
Univentricular Heart

Intervention / Treatment
-----------------
* Drug: Aesculus Hippocastanum / Horse Chestnut
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Underwent Fontan surgery Exclusion Criteria: Severe adverse reaction Personal or parental request

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Interventional Model Description: Patients will be randomized to receive Aesculus hippocastanum or placebo for 4 months, followed by 4 weeks of washout and crossover.
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Aesculus hippocastanum<br>Patients will receive extract of Aesculus hippocastanum | Drug: Aesculus Hippocastanum / Horse Chestnut<br>* Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.<br>|
| Placebo Comparator: Placebo<br>Patients will receive placebo | Drug: Placebo<br>* Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mesenteric artery resistance | Mesenteric artery resistance, measured by pulsed-wave Doppler, in 0.1 units | After 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fontan operation, Aesculus hippocastanum, mesenteric artery resistance
Accuracy Evaluation of SIS Software-based Visualization of New Anatomical Brain Structure

Study Overview
=================
Brief Summary
-----------------
SIS has developed a software technology, based on machine learning and image processing, designed to enhance standard clinical images for the visualization of anatomical structures.

Detailed Description
-----------------
A cohort of 34 subjects will be scanned on a clinical MRI scanner as well as on a 7 Tesla (7T) scanner. Images acquired on the 7T allow to visualize anatomical structures that are not easily identified on standard clinical images. SIS software will be used to visualize selected anatomical features on the clinical image and the results will be compared with the images in the same subject obtained from the 7T MRI.

Official Title
-----------------
Accuracy Evaluation for Software-based Visualization of GPi/GPe Anatomical Brain Structure Using Surgical Information Sciences Inc. Algorithms

Conditions
-----------------
Software Evaluation for Visualizing Anatomical Structures Not Typically Identified on Clinical MR Images

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All subjects that are willing to be scanned on a 3T and 7T MRI scanners and are not excluded by the exclusion criteria below. Exclusion Criteria: MRI exclusion criteria for 7T scans: presence of any metallic clip(s) or implantable medical devices (e.g,. heart valve, aneurysm clip, coils or surgery, renal or aortic clips, shunts, stents or stent grafts, metal mesh/coil implants, neurostimulator, insulin pump, IVC filter, artificial knee or hip, metal plates, pins, screws or wires anywhere in the body, any other metal implants, etc. Pregnant women. Subject under the age of 18.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MRI Data Collection<br>A group of 34 subjects will be scanned on a 3Tesla (3T) and on a 7T MRI scanner. The images will be compared. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Validation of the accurate visualization of brain structure based on SIS algorithms - 1 | Difference in distance between brain structure center of mass (COM) | Through study completion, up to 1 year | 
| Validation of the accurate visualization of brain structure based on SIS algorithms - 2 | Difference in distance between brain structure mean surface area | Through study completion, up to 1 year | 
| Validation of the accurate visualization of brain structure based on SIS algorithms - 3 | Difference in Dice Coefficient between measured brain structures | Through study completion, up to 1 year |
Study to Characterize Effects of Programming in SCS Patients Undergoing a Temporary Trial

Study Overview
=================
Brief Summary
-----------------
This is a prospective, multi-center, non-randomized, exploratory, single-arm study characterize the effects of programming spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial

Official Title
-----------------
Study to Characterize the Effects of Programming Spinal Cord Stimulation (SCS) in Patients Undergoing a Boston Scientific (BSC) SCS Temporary Trial

Conditions
-----------------
Chronic Pain

Intervention / Treatment
-----------------
* Device: Programming


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Study candidate is undergoing a spinal cord stimulation (SCS) trial of BSC neurostimulation system, per local directions for use (DFU). Subject signed a valid, Institutional Review Board (IRB)-approved informed consent form. Subject is 18 years of age or older when written informed consent is obtained. Key Exclusion Criteria: Subject meets any contraindication in BSC neurostimulation system local directions for use (DFU).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Spinal cord stimulation<br>Spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial | Device: Programming<br>* Programming spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Comfort | Number of participants reporting comfort level of stimulation sensation as Very Comfortable or Slightly Comfortable | An estimated average of 7 days post temporary trial procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stimulation, chronic pain, back pain, leg pain
Scheduled Triple-lumen Central Venous Catheter Exchange: A Prospective Controlled Randomized Study

Study Overview
=================
Brief Summary
-----------------
CVC Pros and Cons of scheduled Triple-lumen Central Venous Catheter Exchange: A Prospective Controlled Randomized Study

Official Title
-----------------
CVC Pros and Cons of Scheduled Triple-lumen Central Venous Catheter Exchange: A Prospective Controlled Randomized Study

Conditions
-----------------
Other Female Genital, Cancer

Intervention / Treatment
-----------------
* Procedure: Placement of a central venous catheter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Patients who require the placement of a central venous catheter for medical purposes and have an absence of infection.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Placement of a central venous catheter|Placement of a central venous catheter|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pros and Cons of scheduled Triple-lumen Central Venous Catheter Exchange |  | 3 years |
Eradication of Prostate Cancer Using F-989

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to confirm the findings of an early study with prostate cancer and to expand our knowledge of treating prostate cancer using F-989.

Official Title
-----------------
Phase II Eradication of Prostate Cancer Using F-989

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Dietary Supplement: Acetogenins


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of prostate cancer Referred to the study by their treating physician Exclusion Criteria: - Any type of treatment before starting study

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Acetogenins<br>Acetogenins twice (BID) per day for 12 months | Dietary Supplement: Acetogenins<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gleason Score | A Gleason Score is obtained from the results of a transrectal needle biopsy of the prostate. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prostate Specific Antigens (PSA) |  | 1 year |
The Role of SNP rs2910164 in Patients Treated With Immune Checkpoint Inhibitors

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to investigate whether the SNP rs2910164 in the pre-miR-146a gene is associated with outcome and toxicity of immune checkpoint inhibitor therapy.

Detailed Description
-----------------
The single nucleotide polymorphism (SNP) rs2910164 within the gene for microRNA-146a (miR-146a) reduces miR-146a expression. Previous studies of the investigators demonstrated that this SNP was associated with increased acute GvHD severity in patients undergoing allogeneic hematopoietic stem cell transplantation. In this prospective, observational study the investigators aim to analyze, whether SNP rs2910164 is associated with severity of immune-related adverse events of immune checkpoint inhibitor therapy. Moreover, association of rs2910164 with outcome parameters will be studied.

Official Title
-----------------
A Single-Center, Prospective, Observational Trial to Analyze the Relationship Between Single Nucleotide Polymorphism rs2910164 and the Efficacy and Safety of Immune Checkpoint Inhibitor Therapy

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: confirmed diagnosis of cancer treatment with an immune checkpoint inhibitor (anti-PD-1, anti-PD-L1 or anti-CTLA4) age ≥ 18 years peripheral blood sample available written informed consent ability to understand the nature of the study and the study related procedures and to comply with them Exclusion Criteria: age < 18 years lack of informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity of immune-related adverse events (irAEs) | according to CTCAE | 2 years | 
| Progression-free survival (PFS) |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
immune checkpoint inhibitor, single nucleotide polymorphism, microRNA